IOVANCE BIOTHERAPEUTICS Files 8-K on Other Events and Financials
Ticker: IOVA · Form: 8-K · Filed: Feb 29, 2024 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Feb 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000041666 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K filing, corporate-update, regulatory-filing
TL;DR
**IOVANCE BIOTHERAPEUTICS just dropped an 8-K on Feb 28, covering 'Other Events' and 'Financials' – keep an eye out for details!**
AI Summary
IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on February 28, 2024, reporting on "Other Events" and "Financial Statements and Exhibits." The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, incorporated in Delaware with IRS Employer Identification No. 75-3254381, has its business address at 825 Industrial Road, Suite 400, San Carlos, CA 94070.
Why It Matters
This filing provides an update on significant events and financial exhibits for IOVANCE BIOTHERAPEUTICS, offering transparency to investors regarding the company's current status.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of 'Other Events' and 'Financial Statements and Exhibits' without specific negative or positive details provided in the excerpt.
Key Numbers
- 001-36860 — Commission File Number (SEC identification for the company's filings)
- 75-3254381 — IRS Employer Identification No. (Tax identification for the company)
- 20240228 — Conformed Period of Report (The period covered by the report)
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- Delaware (company) — State of Incorporation
- 75-3254381 (dollar_amount) — I.R.S. Employer Identification No.
- February 28, 2024 (date) — Date of Report
- 825 Industrial Road , Suite 400 San Carlos (company) — Business Address
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is IOVANCE BIOTHERAPEUTICS, INC.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 28, 2024.
In which state is IOVANCE BIOTHERAPEUTICS, INC. incorporated?
IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware.
What is the Commission File Number for IOVANCE BIOTHERAPEUTICS, INC.?
The Commission File Number for IOVANCE BIOTHERAPEUTICS, INC. is 001-36860.
What items are reported in this 8-K filing?
This 8-K filing reports on "Other Events" and "Financial Statements and Exhibits."
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 9.8 · Accepted 2024-02-29 07:30:45
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke
Filing Documents
- tm247560d1_8k.htm (8-K) — 25KB
- tm247560d1_ex99-1.htm (EX-99.1) — 51KB
- tm247560d1_ex99-1img01.jpg (GRAPHIC) — 371KB
- tm247560d1_ex99-1img02.jpg (GRAPHIC) — 1614KB
- tm247560d1_ex99-1img03.jpg (GRAPHIC) — 562KB
- tm247560d1_ex99-1img04.jpg (GRAPHIC) — 607KB
- tm247560d1_ex99-1img05.jpg (GRAPHIC) — 512KB
- tm247560d1_ex99-1img06.jpg (GRAPHIC) — 482KB
- tm247560d1_ex99-1img07.jpg (GRAPHIC) — 961KB
- tm247560d1_ex99-1img08.jpg (GRAPHIC) — 525KB
- tm247560d1_ex99-1img09.jpg (GRAPHIC) — 394KB
- tm247560d1_ex99-1img10.jpg (GRAPHIC) — 258KB
- tm247560d1_ex99-1img11.jpg (GRAPHIC) — 389KB
- tm247560d1_ex99-1img12.jpg (GRAPHIC) — 795KB
- tm247560d1_ex99-1img13.jpg (GRAPHIC) — 671KB
- tm247560d1_ex99-1img14.jpg (GRAPHIC) — 451KB
- tm247560d1_ex99-1img15.jpg (GRAPHIC) — 442KB
- tm247560d1_ex99-1img16.jpg (GRAPHIC) — 491KB
- tm247560d1_ex99-1img17.jpg (GRAPHIC) — 454KB
- tm247560d1_ex99-1img18.jpg (GRAPHIC) — 422KB
- tm247560d1_ex99-1img19.jpg (GRAPHIC) — 489KB
- tm247560d1_ex99-1img20.jpg (GRAPHIC) — 513KB
- tm247560d1_ex99-1img21.jpg (GRAPHIC) — 582KB
- tm247560d1_ex99-1img22.jpg (GRAPHIC) — 384KB
- tm247560d1_ex99-1img23.jpg (GRAPHIC) — 451KB
- tm247560d1_ex99-1img24.jpg (GRAPHIC) — 532KB
- tm247560d1_ex99-1img25.jpg (GRAPHIC) — 604KB
- tm247560d1_ex99-1img26.jpg (GRAPHIC) — 289KB
- tm247560d1_ex99-1img27.jpg (GRAPHIC) — 474KB
- tm247560d1_ex99-1img28.jpg (GRAPHIC) — 300KB
- tm247560d1_ex99-1img29.jpg (GRAPHIC) — 627KB
- tm247560d1_ex99-1img30.jpg (GRAPHIC) — 526KB
- tm247560d1_ex99-1img31.jpg (GRAPHIC) — 564KB
- tm247560d1_ex99-1img32.jpg (GRAPHIC) — 446KB
- tm247560d1_ex99-1img33.jpg (GRAPHIC) — 262KB
- tm247560d1_ex99-1img34.jpg (GRAPHIC) — 413KB
- tm247560d1_ex99-1img35.jpg (GRAPHIC) — 476KB
- tm247560d1_ex99-1img36.jpg (GRAPHIC) — 726KB
- tm247560d1_ex99-1img37.jpg (GRAPHIC) — 362KB
- 0001104659-24-029057.txt ( ) — 26884KB
- iova-20240228.xsd (EX-101.SCH) — 3KB
- iova-20240228_lab.xml (EX-101.LAB) — 33KB
- iova-20240228_pre.xml (EX-101.PRE) — 22KB
- tm247560d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On February 28, 2024, Iovance Biotherapeutics, Inc. (the "Company") updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events is attached as Exhibit 99.1 and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Iovance Biotherapeutics, Inc., Corporate Presentation - February 28, 2024 104 Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 29, 2024 IOVANCE BIOTHERAPEUTICS, INC. By: /s/ Frederick G. Vogt Frederick G. Vogt, Interim CEO & General Counsel